Opinion - Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
Opinion - Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
复制标题
DOI：
10.1038/nrc2173
复制
发表时间：
2007-07-01
影响因子：
78.5
通讯作者：
Piccart, Martine J.
中科院分区：
文献类型：
--
作者：
Sotiriou, Christos;Piccart, Martine J.
微阵列技术的出现使科学家能够同时研究数千个基因的表达。基因表达谱研究提供了乳腺癌临床相关亚型的分子分类，预测疾病复发和对不同治疗反应的新工具，以及对各种致癌途径和转移进展过程的新见解。在这里，我们描述了乳腺癌基因表达研究的最新进展，并考虑了它们目前的局限性和未来的前景。我们还讨论了分子特征对个体乳腺癌患者管理产生影响的潜力，并最终加速经验医学和定制医学之间的过渡。
The advent of microarray technology has enabled scientists to simultaneously investigate the expression of thousands of genes. Gene-expression profiling studies have provided a molecular classification of breast cancer into clinically relevant subtypes, new tools to predict disease recurrence and response to different treatments, and new insights into various oncogenic pathways and the process of metastatic progression. Here we describe the state of the art of gene-expression studies in breast cancer, and consider both their current limitations and future promises. We also discuss the potential of molecular signatures to have an impact on individual breast cancer patient management, and ultimately to accelerate the transition between empirical and tailored medicine.